Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential moxifloxacin versus piperacillin/tazobactam followed by amoxicillin/clavulanic acid for complicated skin and skin structure infections
2006-001599-18Phase 3Completed
- Sponsor
- Bayer
- Start
- Jul 2006
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in skin and soft tissue infections (SSTIs) comparing Sequential moxifloxacin with Piperacillin/tazobactam then amoxicillin/clavulanic acid (2 arms). Primary endpoint: Clinical response at test-of-cure. Started Jul 2006; status: completed.
02
Drugs
moxifloxacinpiperacillin + tazobactamamoxicillin + clavulanate
03
Conditions
skin and soft tissue infections (SSTIs)
Beyond the preview
Go deeper on 2006-001599-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001599-18.